Cost-Effectiveness Analysis of Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes in China

Speaker(s)

Liu L1, Zhen R2, Ung COL3, Shen Y4, Zhang Y4, Han S5, Jia R6, Qiao J7, Hu H3, Guo L7
1Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China, 2Institute of Chinese Medical Sciences, University of Macau, Beijing, 11, China, 3Institute of Chinese Medical Sciences, University of Macau, Macau, 11, China, 4Novo Nordisk (China) Pharmaceuticals Co., Ltd, Beijing, China, 5International Research Center for Medicinal Administration, Peking University, Beijing, China, 6University College London, London, UK, 7Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China

Presentation Documents

OBJECTIVES: To assess the long-term cost-effectiveness of once-weekly (OW) semaglutide 0.5mg and 1.0mg versus Polyethylene Glycol Loxenatide (PEG-Loxenatide) 0.2mg (a Chinese self-developed once-weekly GLP-1RA) among patients with type 2 diabetes (T2D) in Chinese setting.

METHODS: The Swedish Institute of Health Economics Diabetes Cohort Model (IHE-DCM, V4.4.2) was used to evaluate the long-term health and economic outcomes between OW semaglutide versus PEG-Loxenatide. Analysis was conducted from the perspective of Chinese healthcare systems over a time horizon of 40 years. Baseline cohort characteristics were sourced from the SUSTAIN China clinical trial. Baseline risks of complications were sourced from previous publication. A network meta-analysis (NMA) based on two placebo-controlled phase 3a clinical trials, which assessed the efficacy of OW semaglutide and PE-Loxenatide respectively, was conducted to obtain the treatment effects of OW semaglutide and PEG-Loxenatide. Pharmaceutical costs were sourced from national bidding price in China. Costs of complications and utilities associated with diabetes and diabetes-related complications were taken from published sources. Costs were expressed in 2021 China Yuan (CNY). Health and economic outcomes were discounted at a rate of 5% annually. Sensitivity analyses were conducted to assess the robustness of the results.

RESULTS: Compared with PEG-Loxenatide 0.2mg, OW semaglutide 0.5mg and 1.0mg were associated with increase discounted life expectancy of 0.08 years and 0.12 years, and with increased discounted quality-adjusted life expectancy of 0.16 QALYs and 0.22 QALYs, respectively. Clinical benefits were achieved at reduced costs, with lifetime cost savings of 19,309 CNY with OW semaglutide 0.5 mg and 10,179 CNY with OW semaglutide 1.0 mg. Sensitivity analyses verified the robustness of the research results.

CONCLUSIONS: Compared with treatment with PEG-Loxenatide, once-weekly semaglutide represents a dominant option for treating patients with T2D in China who are not achieving glycemic control with metformin, projected to both improve clinical outcomes and reduce costs.

Code

EE315

Topic

Clinical Outcomes, Economic Evaluation, Study Approaches

Topic Subcategory

Clinical Outcomes Assessment, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Decision Modeling & Simulation

Disease

SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity)